Edralbrutinib

CAS No. 1858206-58-2

Edralbrutinib( —— )

Catalog No. M35710 CAS No. 1858206-58-2

Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity used in treating tumors, immune system disorders, and blood and lymphatic system disorders.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 187 In Stock
10MG 301 In Stock
25MG 506 In Stock
50MG 706 In Stock
100MG 918 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Edralbrutinib
  • Note
    Research use only, not for human use.
  • Brief Description
    Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity used in treating tumors, immune system disorders, and blood and lymphatic system disorders.
  • Description
    Edralbrutinib (TG-1701) is a potent BTK inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Tyrosine Kinase
  • Target
    BTK
  • Recptor
    BTK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1858206-58-2
  • Formula Weight
    489.47
  • Molecular Formula
    C26H21F2N5O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C1C2=C(C(=CN2[C@H]3CN(C(C#CC)=O)CC3)C4=CC=C(OC5=C(F)C=CC=C5F)C=C4)C(N)=NN1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. JIANGSU HENGRUI MEDICINE CO, et al. Pharmaceutically acceptable salt and crystal form of pyrrolo[2,3-d]pyridazin-7-one derivative and preparation method of medicinal salt and crystal form. WO2018210296A1.
molnova catalog
related products
  • Larotinib

    Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.

  • BLK degrader 1

    BLK degrader 1 is a selective B lymphoid tyrosine kinase (BLK) degrader with anticancer activity and can be used for cancer research.

  • NX-2127

    NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative activity and inhibits the proliferation of BTKC481S mutant TMD8 cells.